Daunorubicin

Description

This page contains brief details about the drug daunorubicin, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Daunorubicin is an anti-cancer drug containing the active constituent daunorubicin. This chemotherapy medication belongs to the anthracycline class of drugs. It is used in the treatment of leukemia. In leukemia, the white blood cells produced in the bone marrow multiply uncontrolled and abnormally. Leukemia is associated with severe infection, extreme tiredness, and joint pain. It is necessary to inform your doctor if you have an infection, cardiac diseases, mouth ulcers, chickenpox or shingles (viral infection), fever, radiation treatment to the chest, kidney stones, and liver disorders.

Daunorubicin was first approved by the FDA in 1979 for the treatment of acute myeloid leukemia (AML). Since then, Daunorubicin has been approved for additional indications and formulations, including for the treatment of solid tumors and lymphomas. Like many chemotherapy drugs, it can cause side effects such as nausea, vomiting, hair loss, fatigue, and an increased risk of infection due to its effect on the immune system.

Mechanism of Action of Daunorubicin

The therapeutic effect of daunorubicin is to inhibit the growth and replication of cancer cells. As a chemotherapy medication, daunorubicin works by binding to DNA and interfering with its replication and transcription, ultimately leading to cell death. Doing so can help shrink tumors, prevent cancer from spreading to other parts of the body, and potentially cure cancer in some cases.

Uses of Daunorubicin

Daunorubicin is primarily used to treat acute myeloid leukemia (AML), a type of cancer that affects the blood and bone marrow. It can also be used to treat other types of cancer, including acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), lymphoma, and solid tumors such as breast and ovarian cancer.

Daunorubicin Dosage available

Daunorubicin is typically administered as an intravenous (IV) infusion or injection in a hospital or clinical setting by a healthcare provider. The exact dosing and frequency of administration will depend on the specific condition being treated and other individual factors, such as the patient’s age, weight, and overall health. If a dose is missed, it’s important to contact your healthcare provider as soon as possible to determine the appropriate course of action. Suppose the missed dose is discovered within a few hours of the scheduled time. In that case, your healthcare provider may recommend administering the missed dose as soon as possible while maintaining the usual interval between doses. However, if more than a few hours have passed since the missed dose, your healthcare provider may recommend skipping the missed dose and resuming the regular dosing schedule at the next scheduled time. It’s important not to double up on doses to make up for a missed one.